MARCH 27
Days
- :
Hrs
- :
Min
- :
Sec
ePoster Gallery
P130: Enhanced sensitivity of indocyanine green versus isosulfan blue for sentinel lymph node biopsy in melanoma
Tannaz Ranjbarian MD Surgery Post-doctoral Research Fellow
University of california san diego
P131: External validation of a model to predict recurrence-free and melanoma-specific survival for patients with melanoma after sentinel node biopsy.
Robert Stassen MD
Erasmus Medical Centre, Cancer Institure
P132: IDH1 modulation sensitizes NRAS mutant melanoma to MEK inhibition
Alexander Loftus
University Hospitals Cleveland Medical Center
P133: Impact of sentinel lymph node biopsy on recurrence and survival for Merkel cell carcinoma
Michelle Dugan MD
Moffitt Cancer Center
P135: Isolated limb infusion/perfusion for unresectable acral versus non-acral melanoma in-transit metastases
Michelle Dugan MD
Moffitt Cancer Center
P136: Local recurrence and survival in patients with melanoma >2 mm in thickness at critical structures treated with 10-mm versus 20-mm margins
Bianca Taglione
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
P137: Melanoma in Peru: 1000 patients and 10 years of experience
Gonzalo Ziegler Rodriguez MD, FACS
Clinica Ziegler
P138: Nodal imaging concordance with pathologic findings after neoadjuvant immunotherapy in patients with Stage III melanoma
Joshua Herb MD, MS
The University of Texas MD Anderson Cancer Center
P141: Melanoma Screening May Not Lead to Improved Outcomes: A Cross-Sectional Study
Trisha Lal
Case Western Reserve/University Hospitals
P142: Patterns of Melanoma Care in a Rural State
Nicholas Callais MD
University of Arkansas for Medical Sciences
P143: Real-world outcomes of patients with clinically node positive melanoma undergoing neoadjuvant immunotherapy and nodal dissection
Joshua Herb MD, MS
The University of Texas MD Anderson Cancer Center
P144: Reduced hepatotoxicity and equivalent survival with a lower hepatic arterial floxuridine starting dose in the adjuvant treatment of colorectal cancer liver metastases
Kevin Labadie
City of Hope
P144: Stagnant Survival Rates in Uveal Melanoma Liver Metastases: The Paradox of Escalating Immunotherapy
Paul Wong BS
University of California, San Francisco
P145: Survival Outcomes of Acral Lentiginous Melanoma in the Era of Modern Immune Checkpoint Inhibitor and Targeted Therapy
Adrienne Shannon MD
Moffitt Cancer Center
P146: Systemic immunotherapy promotes equivalent survival between pathologic stage III cutaneous melanoma subtypes
Avia Wilkerson MD, PhD
Cleveland Clinic - Cleveland, OH
P147: The economic impact of regional communities of practice to improve quality of melanoma care
Laura Kerr MD, FRCSC
University of Ottawa
P148: The Impact of Second Pathologic Review in the Management of Patients with Malignant Melanoma
Angelina Wang
University of California Irvine Department of Surgical Oncology
P149: The Impact of Talimogene Laherparepvec (T-VEC) on Survival in In-Transit Disease From Acral Lentiginous Melanoma
Adrienne Shannon MD
Moffitt Cancer Center